HK1175947A1 - 醫藥組合物及其製備方法 - Google Patents

醫藥組合物及其製備方法

Info

Publication number
HK1175947A1
HK1175947A1 HK13103191.6A HK13103191A HK1175947A1 HK 1175947 A1 HK1175947 A1 HK 1175947A1 HK 13103191 A HK13103191 A HK 13103191A HK 1175947 A1 HK1175947 A1 HK 1175947A1
Authority
HK
Hong Kong
Prior art keywords
methods
pharmaceutical compositions
making same
making
same
Prior art date
Application number
HK13103191.6A
Other languages
English (en)
Inventor
Manish K Gupta
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of HK1175947A1 publication Critical patent/HK1175947A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK13103191.6A 2010-05-05 2013-03-14 醫藥組合物及其製備方法 HK1175947A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33171510P 2010-05-05 2010-05-05
PCT/US2011/035363 WO2011140343A1 (en) 2010-05-05 2011-05-05 Pharmaceutical compositions and methods of making same

Publications (1)

Publication Number Publication Date
HK1175947A1 true HK1175947A1 (zh) 2013-07-19

Family

ID=44851507

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13103191.6A HK1175947A1 (zh) 2010-05-05 2013-03-14 醫藥組合物及其製備方法

Country Status (26)

Country Link
US (3) US20110281901A1 (zh)
EP (1) EP2566331B1 (zh)
JP (1) JP5835717B2 (zh)
KR (1) KR20130071434A (zh)
CN (1) CN102970871A (zh)
AR (1) AR081364A1 (zh)
AU (1) AU2011247995B2 (zh)
BR (1) BR112012028291A2 (zh)
CA (1) CA2798386A1 (zh)
CL (1) CL2012003075A1 (zh)
CO (1) CO6640262A2 (zh)
CR (1) CR20120556A (zh)
DO (1) DOP2012000281A (zh)
EA (1) EA201291168A1 (zh)
ES (1) ES2519615T3 (zh)
HK (1) HK1175947A1 (zh)
IL (1) IL222751A0 (zh)
MA (1) MA34286B1 (zh)
MX (1) MX2012012837A (zh)
NZ (1) NZ603411A (zh)
PE (1) PE20130217A1 (zh)
SG (1) SG185087A1 (zh)
TW (1) TW201206908A (zh)
UY (1) UY33367A (zh)
WO (1) WO2011140343A1 (zh)
ZA (1) ZA201208265B (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2013040247A2 (en) 2011-09-16 2013-03-21 Forsight Vision4, Inc. Fluid exchange apparatus and methods
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
EP2824981B1 (en) * 2012-03-08 2019-02-27 Samsung Electronics Co., Ltd. Method for controlling service in radio communication system
EP2968113B8 (en) * 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
EP3039424B1 (en) 2013-08-28 2020-07-29 Crown Bioscience, Inc. (Taicang) Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
SG11201700943TA (en) 2014-08-08 2017-03-30 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
EP3217924A4 (en) 2014-11-10 2018-07-11 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
JP6818264B2 (ja) 2014-12-25 2021-01-20 国立大学法人京都大学 高密度リポタンパク質およびその細胞親和性ペプチドを融合した高密度リポタンパク質の点眼による後眼部薬物デリバリー
JP7009384B2 (ja) 2016-04-05 2022-01-25 フォーサイト・ビジョン フォー・インコーポレーテッド 移植可能な眼薬送達デバイス
WO2018192416A1 (en) * 2017-04-17 2018-10-25 National Institute Of Biological Sciences, Beijing Treating Male Senescence
TWI770246B (zh) * 2017-08-02 2022-07-11 昊運股份有限公司 新穎化合物及包含其之醫藥組成物
KR20230142810A (ko) * 2018-06-07 2023-10-11 화이자 인코포레이티드 1-(4-｛[4-(디메틸아미노)피페리딘-1-일]카르보닐｝페닐)-3-[4-(4,6-디모르폴린-4-일-1,3,5-트리아진-2-일)페닐]우레아를 포함하는 수성 제제
CN113350351A (zh) * 2020-03-13 2021-09-07 青晓制药公司 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
US20240050429A1 (en) * 2022-08-10 2024-02-15 Qx Therapeutics, Inc. Pazopanib pharmaceutical composition, injection and preparation method and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
NZ572226A (en) * 2006-04-18 2011-05-27 Ekr Therapeutics Inc Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use
CA2702984C (en) * 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
CN101981037B (zh) * 2008-01-30 2013-09-04 吉宁特有限公司 吡唑并嘧啶pi3k抑制剂化合物及使用方法
US20120165354A1 (en) * 2009-07-16 2012-06-28 Glaxo Wellcome Manufacturing Pte Ltd. Treatment method
WO2011039648A1 (en) * 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
UY33164A (es) * 2010-01-06 2011-08-31 Glaxo Wellcome Mfg Pte Ltd Metodo de tratamiento
US20130023550A1 (en) * 2010-05-05 2013-01-24 Glaxo Wellcome Manufacturing Pte, Ltd Pharmaceutical compositions and methods of making same
UY33367A (es) * 2010-05-05 2011-10-31 Glaxo Wellcome Mfg Pte Ltd Composiciones farmacéuticas y métodos para su elaboración

Also Published As

Publication number Publication date
KR20130071434A (ko) 2013-06-28
CL2012003075A1 (es) 2013-03-08
US20120028918A1 (en) 2012-02-02
JP5835717B2 (ja) 2015-12-24
US20150231265A1 (en) 2015-08-20
IL222751A0 (en) 2012-12-31
CN102970871A (zh) 2013-03-13
MA34286B1 (fr) 2013-06-01
EP2566331B1 (en) 2014-09-03
EP2566331A1 (en) 2013-03-13
EA201291168A1 (ru) 2013-06-28
PE20130217A1 (es) 2013-03-21
ZA201208265B (en) 2013-07-31
UY33367A (es) 2011-10-31
NZ603411A (en) 2014-10-31
TW201206908A (en) 2012-02-16
MX2012012837A (es) 2013-01-24
CA2798386A1 (en) 2011-11-10
DOP2012000281A (es) 2013-05-31
ES2519615T3 (es) 2014-11-07
WO2011140343A1 (en) 2011-11-10
SG185087A1 (en) 2012-12-28
BR112012028291A2 (pt) 2015-09-15
EP2566331A4 (en) 2013-09-18
AR081364A1 (es) 2012-08-29
CO6640262A2 (es) 2013-03-22
CR20120556A (es) 2013-02-20
AU2011247995A1 (en) 2012-12-13
US20110281901A1 (en) 2011-11-17
JP2013525501A (ja) 2013-06-20
AU2011247995B2 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
IL265327A (en) xten duo preparations and methods for their production
HK1250313A1 (zh) 穩定的藥物組合物和使用所述組合物的方法
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
HK1175947A1 (zh) 醫藥組合物及其製備方法
EP2536756A4 (en) HSA-RELATED COMPOSITIONS AND USE PROCESSES
EP2584897A4 (en) COMPOSITIONS CONTAINING RESVERATROL AND METHODS OF USE
EP2569425A4 (en) ENDORIBONUCLEASE COMPOSITIONS AND METHOD FOR THEIR USE
EP2521553A4 (en) METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS
IL222291A0 (en) Compositions and methods of synthesis of pyridinoylpiperidine
EP2593571A4 (en) SWEETENER COMPOSITIONS AND METHODS OF PRODUCING THE SAME
EP2596112A4 (en) ACETYCYSTEIN COMPOSITIONS AND USE METHOD THEREFOR
GB2478849A8 (en) Improved pharmaceutical compositions and methods of delivery
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
EP2616053A4 (en) PHARMACEUTICAL COMPOSITIONS FROM CURCUMIN
EP2539444A4 (en) COMPOSITIONS AND METHODS FOR THE PRODUCTION OF L-HOMOALANINE
IL220715A0 (en) Nutritive compositions and methods of using same
SG10201604468QA (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
IL219018A (en) Radzolid Pharmaceuticals and Uses
GB201002278D0 (en) composition and method of preparation

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190502